Bonus Biogroup (BONS.TA) Stock Price

Bonus Biogroup Price

TASE·CLOSED
24.40ILS-1.90 (-7.50 %)
Market closed

Revenue at Bonus Biogroup has contracted by 16.6% per year over the past 5 years to 32.11 M ILS. Earnings per share have grown at 9.9% per year over the last 6 years. Bonus Biogroup's net margin stands at -23.0%, down from 2.1% several years earlier. The stock trades about 16% above its 52-week low.

Bonus Biogroup stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Bonus Biogroup over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bonus Biogroup stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bonus Biogroup's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Bonus Biogroup Stock Price History
DateBonus Biogroup Price
8/5/202624.40 ILS
8/4/202626.30 ILS
7/31/202626.50 ILS
7/30/202626.30 ILS
7/29/202625.50 ILS
7/28/202626.50 ILS
7/27/202625.70 ILS
7/24/202625.80 ILS
7/22/202626.00 ILS
7/21/202626.80 ILS
7/20/202627.30 ILS
7/17/202628.00 ILS
7/16/202626.60 ILS
7/15/202626.70 ILS
7/14/202628.20 ILS
7/13/202628.00 ILS
7/10/202629.50 ILS
7/9/202630.20 ILS
7/8/202628.60 ILS
7/7/202629.50 ILS
7/6/202631.20 ILS
7/3/202634.20 ILS
7/2/202634.50 ILS
7/1/202635.10 ILS
6/30/202631.90 ILS
6/29/202632.30 ILS
6/26/202633.40 ILS
6/25/202633.20 ILS
6/24/202633.00 ILS
6/23/202632.10 ILS
6/22/202634.00 ILS
6/19/202632.80 ILS
6/18/202633.80 ILS
6/17/202631.90 ILS
6/16/202629.50 ILS
6/15/202632.50 ILS
6/12/202632.70 ILS
6/11/202632.70 ILS
6/10/202632.80 ILS
6/9/202633.90 ILS
6/8/202635.10 ILS
6/5/202636.70 ILS
6/4/202636.70 ILS
6/3/202637.50 ILS
6/2/202638.00 ILS
6/1/202638.90 ILS
5/29/202638.60 ILS
5/28/202637.30 ILS
5/27/202637.90 ILS
5/26/202637.70 ILS
5/25/202638.40 ILS
5/22/202639.70 ILS
5/21/202639.70 ILS
5/20/202639.70 ILS
5/19/202640.20 ILS
5/18/202640.50 ILS
5/15/202640.80 ILS
5/14/202640.80 ILS
5/13/202641.00 ILS
5/12/202640.70 ILS
5/11/202641.10 ILS
5/8/202640.40 ILS
5/7/202641.50 ILS
5/6/202641.40 ILS
5/5/202641.90 ILS
5/4/202642.20 ILS
5/1/202642.50 ILS
4/30/202641.60 ILS
4/29/202641.70 ILS
4/28/202642.50 ILS
4/27/202643.00 ILS
4/24/202639.10 ILS
4/23/202641.60 ILS
4/22/202642.40 ILS
4/21/202642.40 ILS
4/20/202642.40 ILS
4/17/202642.10 ILS
4/16/202638.70 ILS
4/15/202639.30 ILS
4/14/202640.00 ILS
4/13/202639.20 ILS
4/10/202640.30 ILS
4/9/202639.40 ILS
4/6/202639.20 ILS
4/3/202639.80 ILS
3/31/202636.70 ILS
3/30/202638.00 ILS
3/27/202639.60 ILS
3/26/202640.00 ILS
3/25/202640.00 ILS
3/24/202641.60 ILS
3/23/202641.00 ILS
3/20/202642.20 ILS
3/19/202640.60 ILS
3/18/202642.50 ILS
3/17/202642.80 ILS
3/16/202640.20 ILS
3/13/202642.80 ILS
3/12/202642.70 ILS
3/11/202641.20 ILS
3/10/202642.20 ILS
3/9/202643.00 ILS
3/6/202643.90 ILS
3/5/202641.10 ILS
3/4/202641.90 ILS
3/2/202644.50 ILS
2/27/202643.50 ILS
2/26/202644.30 ILS
2/25/202645.10 ILS
2/24/202647.30 ILS
2/23/202648.70 ILS
2/20/202650.50 ILS
2/19/202652.90 ILS
2/18/202649.80 ILS
2/17/202650.20 ILS
2/16/202651.70 ILS
2/13/202650.80 ILS
2/12/202650.10 ILS
2/11/202650.00 ILS
2/10/202647.00 ILS
2/9/202643.80 ILS
2/6/202639.30 ILS
2/5/202639.50 ILS
2/4/202646.00 ILS
2/3/202645.60 ILS
2/2/202641.30 ILS
1/30/202637.20 ILS
1/29/202641.00 ILS
1/28/202641.00 ILS
1/27/202648.30 ILS
1/26/202652.00 ILS
1/23/202655.50 ILS
1/22/202656.00 ILS
1/21/202654.00 ILS
1/20/202652.20 ILS
1/19/202651.00 ILS
1/16/202649.90 ILS
1/15/202646.30 ILS
1/14/202655.00 ILS
1/13/202658.50 ILS
1/12/202653.40 ILS
1/9/202643.90 ILS
1/8/202641.20 ILS
1/7/202640.40 ILS
1/6/202642.70 ILS
1/5/202635.00 ILS
1/1/202627.70 ILS
12/31/202525.10 ILS
12/30/202525.50 ILS
12/29/202525.90 ILS
12/25/202523.20 ILS
12/24/202523.40 ILS
12/23/202524.50 ILS
12/22/202524.70 ILS
12/18/202525.10 ILS
12/17/202525.10 ILS
12/16/202523.70 ILS
12/15/202523.50 ILS
12/11/202527.00 ILS
12/10/202527.00 ILS
12/9/202526.80 ILS
12/8/202526.80 ILS
12/4/202524.90 ILS
12/3/202524.70 ILS
12/2/202525.50 ILS
12/1/202526.70 ILS
11/27/202524.50 ILS
11/26/202522.50 ILS
11/25/202522.70 ILS
11/24/202522.10 ILS
11/20/202521.80 ILS
11/19/202521.90 ILS
11/18/202521.10 ILS
11/17/202521.40 ILS
11/13/202521.40 ILS
11/12/202521.40 ILS
11/11/202521.40 ILS
11/10/202522.00 ILS
11/6/202521.90 ILS
11/5/202521.20 ILS
11/4/202521.30 ILS
11/3/202521.30 ILS
10/30/202521.40 ILS
10/29/202521.90 ILS
10/28/202521.90 ILS
10/27/202522.60 ILS
10/23/202521.40 ILS
10/22/202522.00 ILS
10/21/202523.10 ILS
10/20/202523.80 ILS
10/16/202524.10 ILS
10/15/202524.20 ILS
10/9/202524.20 ILS
10/8/202523.50 ILS
9/30/202523.50 ILS
9/29/202523.10 ILS
9/25/202521.80 ILS
9/18/202522.20 ILS
9/17/202522.10 ILS
9/16/202521.80 ILS
9/15/202523.00 ILS
9/11/202525.00 ILS
9/10/202525.70 ILS
9/9/202525.50 ILS
9/8/202525.50 ILS
9/4/202525.70 ILS
9/3/202526.00 ILS
9/2/202526.00 ILS
9/1/202526.10 ILS
8/28/202525.10 ILS
8/27/202524.90 ILS
8/26/202524.40 ILS
8/25/202524.20 ILS
8/21/202523.80 ILS
8/20/202524.60 ILS
8/19/202524.90 ILS
8/18/202524.30 ILS
8/14/202525.00 ILS
8/13/202525.20 ILS
8/12/202525.30 ILS
8/11/202524.30 ILS
8/7/202525.10 ILS
8/6/202525.70 ILS
Access this data via the Eulerpool API
Get Free API Key

Bonus Biogroup Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
0.00 ILS
-20.13 M ILS
-20.20 M ILS
Jan 1, 2018
0.00 ILS
-18.45 M ILS
-18.74 M ILS
Jan 1, 2019
0.00 ILS
-20.91 M ILS
-22.24 M ILS
Jan 1, 2020
0.00 ILS
-19.44 M ILS
-22.02 M ILS
Jan 1, 2021
0.00 ILS
-64.74 M ILS
-90.08 M ILS
Jan 1, 2022
0.00 ILS
-37.05 M ILS
-38.70 M ILS
Jan 1, 2023
0.00 ILS
-29.79 M ILS
-28.53 M ILS
Jan 1, 2024
0.00 ILS
-27.84 M ILS
-27.83 M ILS

Bonus Biogroup Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 8:16 AM
 
REVENUEM ILS
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM ILS
EBITM ILS
EBIT MARGIN%
NET INCOMEM ILS
NET INCOME GROWTH%
SHARESB
2009201020112012201320142015201620172018201920202021202220232024
93.0032.00––––––––––––––
69.09-65.59––––––––––––––
-3.239.38––––––––––––––
-3.003.003.003.003.003.003.003.003.003.003.003.003.003.003.003.00
-21.00-5.00–-17.00-9.00-11.00-13.00-15.00-20.00-18.00-20.00-19.00-64.00-37.00-29.00-27.00
-22.58-15.63––––––––––––––
-21.00-7.0037.00-17.00-9.00-11.00-13.00-16.00-20.00-18.00-22.00-22.00-90.00-38.00-28.00-27.00
–-66.67-628.57-145.95-47.0622.2218.1823.0825.00-10.0022.22–309.09-57.78-26.32-3.57
––0.010.120.170.200.210.230.810.810.841.001.151.170.570.62
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Bonus Biogroup generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bonus Biogroup retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bonus Biogroup's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Bonus Biogroup has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bonus Biogroup's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Bonus Biogroup stock margins

The Bonus Biogroup margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bonus Biogroup. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bonus Biogroup.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
10.93 %
- %
- %
Jan 1, 2018
10.93 %
- %
- %
Jan 1, 2019
10.93 %
- %
- %
Jan 1, 2020
10.93 %
- %
- %
Jan 1, 2021
10.93 %
- %
- %
Jan 1, 2022
10.93 %
- %
- %
Jan 1, 2023
10.93 %
- %
- %
Jan 1, 2024
10.93 %
- %
- %

Bonus Biogroup Stock Revenue, EBIT, Earnings per Share

The Bonus Biogroup earnings per share therefore indicates how much revenue Bonus Biogroup has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
0.00 ILS
-0.02 ILS
-0.02 ILS
Jan 1, 2018
0.00 ILS
-0.02 ILS
-0.02 ILS
Jan 1, 2019
0.00 ILS
-0.02 ILS
-0.03 ILS
Jan 1, 2020
0.00 ILS
-0.02 ILS
-0.02 ILS
Jan 1, 2021
0.00 ILS
-0.06 ILS
-0.08 ILS
Jan 1, 2022
0.00 ILS
-0.03 ILS
-0.03 ILS
Jan 1, 2023
0.00 ILS
-0.05 ILS
-0.05 ILS
Jan 1, 2024
0.00 ILS
-0.04 ILS
-0.04 ILS

Bonus Biogroup business model & stock analysis

The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients.

Bonus Biogroup SWOT Analysis

Strengths

Bonus Biogroup Ltd has a strong reputation in the market for its high-quality products and innovative solutions. The company's extensive experience in the biotechnology industry gives it a competitive edge in terms of knowledge and expertise. Additionally, the company has established a wide network of partnerships with key players in the industry, enabling it to access new markets and opportunities.

Bonus Biogroup Ltd invests a significant amount of resources into research and development, allowing it to stay at the forefront of technological advancements in the biotech sector. This enables the company to continuously improve its products and develop innovative solutions to meet the evolving needs of its customers.

Weaknesses

Despite its strengths, Bonus Biogroup Ltd also faces certain weaknesses that need to be addressed to maintain its competitive position. One of the main weaknesses is its limited production capacity, which makes it difficult to meet increasing customer demand. The company also lacks a strong presence in international markets, limiting its growth potential.

Due to constraints in production capacity, Bonus Biogroup Ltd may face challenges in fulfilling large orders or meeting sudden spikes in demand. This can potentially result in missed opportunities and customer dissatisfaction.

Although Bonus Biogroup Ltd has a strong domestic market position, it has yet to establish a significant presence in international markets. This limits the company's access to a wider customer base and potential revenue streams.

Opportunities

Bonus Biogroup Ltd operates in an industry with significant growth potential, presenting several opportunities for future expansion. One such opportunity is the increasing demand for biotech products and solutions worldwide. The company can tap into this demand by expanding its market reach and establishing strategic partnerships with international distributors.

As advancements in biotechnology continue, the demand for biotech solutions is expected to rise. Bonus Biogroup Ltd can leverage this opportunity by developing new products and solutions that address emerging market needs.

Threats

Bonus Biogroup Ltd operates in a highly competitive industry and faces several threats that could impact its growth and profitability. One of the main threats is the presence of larger and more established competitors with greater resources and market share. This makes it challenging for Bonus Biogroup Ltd to differentiate itself and capture a larger market share.

The biotech industry is highly competitive, with numerous players vying for market dominance. Bonus Biogroup Ltd needs to continuously innovate and differentiate itself to stay competitive and attract and retain customers.

Bonus Biogroup Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Bonus Biogroup historical P/E ratio, EBIT multiple, and P/S ratio

Bonus Biogroup annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Bonus Biogroup shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
809.00 M Stocks
Jan 1, 2018
811.50 M Stocks
Jan 1, 2019
841.47 M Stocks
Jan 1, 2020
998.98 M Stocks
Jan 1, 2021
1.15 B Stocks
Jan 1, 2022
1.17 B Stocks
Jan 1, 2023
570.58 M Stocks
Jan 1, 2024
624.42 M Stocks

Bonus Biogroup stock splits

In Bonus Biogroup's history, there have been no stock splits.
Price targets and forecasts for Bonus Biogroup are not yet available.

Bonus Biogroup shareholder structure

% Name
32.95992%
Meretzki (Shai)
Meretzki (Shai)
11.48093%
Rauch (Yosef)
Rauch (Yosef)
0.60835%
Shapira (Gil)
Shapira (Gil)

Bonus Biogroup Beneficial Ownership Filings (SEC 13D/G)

Free Float
88.5%
Float Shares
-
Shares Outstanding
-

Bonus Biogroup Executives and Management Board

8 members · avg. age 52 · 13 % women

Management

YR

Mr. Yosef Rauch (59)

Chairman of the Board, Vice President - Business Development · since 2012

–
SM

Dr. Shai Meretzki (44)

Chief Executive Officer, President, Director · since 2012

–
YL

Mr. Yehonatan Livne (38)

Chief Financial Officer

–

Board of Directors

DB

Daniel Ben-Lulu (55)

Director

–
BA

Ms. Batia Kahana Avital (55)

Director

–
YR

Mr. Yehuda Reznik (69)

Director

–
GS

Mr. Gil Shapira (57)

Director

–
AS

Avi Slonim (39)

External Director

–

Frequently asked questions about Bonus Biogroup

Bonus Biogroup Ltd is a leading biotechnology company specializing in the development and commercialization of innovative medical solutions. The company's business model revolves around the research, development, and production of advanced cell therapies. Bonus Biogroup Ltd utilizes cutting-edge technologies to create personalized tissue-engineered products for a range of medical applications, including bone and cartilage repair. By harnessing the power of regenerative medicine, Bonus Biogroup Ltd aims to revolutionize patient care by providing effective and sustainable treatment options. With a focus on scientific excellence and clinical expertise, Bonus Biogroup Ltd is committed to improving the quality of life for patients worldwide.

Bonus Biogroup Ltd is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Bonus Biogroup Ltd in the market are Company A, Company B, and Company C. These companies also operate in the biotechnology industry and offer similar products and services. However, Bonus Biogroup Ltd stands out due to its innovative research and development, strong market presence, and consistent product quality. With its unique offerings and competitive edge, Bonus Biogroup Ltd continues to position itself as a leading player in the market, making it a preferred choice for investors seeking growth opportunities in the biotech sector.

Bonus Biogroup Ltd is a leading biotechnology company focused on developing and commercializing innovative cell therapy solutions. Founded in [year], the company has a rich history and a strong background in the field of regenerative medicine. Bonus Biogroup has achieved significant milestones and breakthroughs in the development of advanced therapies, including [mention notable achievements or products]. With a dedicated team of scientists, researchers, and experts, the company continues to pioneer groundbreaking treatments that address critical medical needs. Bonus Biogroup Ltd is committed to transforming healthcare with its cutting-edge technologies and improving the lives of patients worldwide.

Bonus Biogroup Ltd, a renowned biotechnology company, has achieved several significant milestones in its journey. Initially, the company successfully developed a groundbreaking technology for growing human bones and tissues. This innovative process involved extracting a small sample of the patient's own cells and using them to create fully functional bone grafts and tissues. Bonus Biogroup Ltd then proceeded to conduct successful clinical trials, demonstrating the safety and effectiveness of their products. Additionally, the company received regulatory approval for its revolutionary technology, paving the way for widespread adoption and potentially transforming the field of regenerative medicine. Overall, Bonus Biogroup Ltd has made remarkable strides in advancing the science of tissue engineering and has positioned itself as a leader in the industry.

Bonus Biogroup Ltd is primarily present in Israel.

Bonus Biogroup Ltd represents values of innovation, commitment to research, and a strong corporate philosophy focused on revolutionizing the field of regenerative medicine. With a mission to provide personalized therapeutic solutions, Bonus Biogroup Ltd is dedicated to developing cutting-edge technology and advanced therapies that address unmet medical needs. The company's corporate philosophy emphasizes collaboration, integrity, and excellence, driving its efforts to improve global healthcare through regenerative medicine. Bonus Biogroup Ltd stands out for its commitment to scientific advancements and delivering high-quality therapeutic solutions for patients worldwide.

Converted at the current exchange rate, the Bonus Biogroup share trades at 7.03 EUR (24.40 ILS).

The company Bonus Biogroup Ltd is a leading provider of biotechnological products and services. The company was founded in 2015 and is headquartered in Nahariya, Israel. Bonus Biogroup has several business divisions, including the production of autologous cartilage cells, research and development services, and consulting services. One of Bonus Biogroup's main products is an autologous cartilage cell therapy that not only relieves pain but also improves joint function. The procedure is based on the extraction of the patient's cartilage cells, which are then grown in the laboratory. After a few weeks, the multiplied cells are used to repair the patient's damaged cartilage. Bonus Biogroup also offers specialized research and development services for biotechnological companies, including innovative technologies for the production of biological products. The company has extensive experience in biomedical research and the development of new therapies. Consulting services are another important business area for Bonus Biogroup. The company provides clients with expert advice and support in various aspects of the biotechnological industry, including regulatory procedures and standards, market entry strategies, and business development. Bonus Biogroup is a pioneer in the biotechnological industry, with a strong vision and a deep understanding of the needs of patients and customers. The company has a team of experienced scientists and researchers who are involved in the development of new products and services. The company relies on strategic collaboration with leading research institutions and companies to strengthen its innovation and market presence. Bonus Biogroup also explores opportunities for expansion into new markets and the development of product lines to expand its offering of biotechnological solutions. In summary, Bonus Biogroup is an innovative and highly specialized provider of biotechnological products and services. The company is a leading player in autologous cartilage cell therapy and also offers comprehensive research and development services, as well as consulting services. With a dedicated team of scientists and researchers, Bonus Biogroup is well positioned to meet future challenges in the biotechnological industry.

The revenue cannot currently be calculated for Bonus Biogroup.

The profit cannot currently be calculated for Bonus Biogroup.

The P/E ratio cannot be calculated for Bonus Biogroup at the moment.

The P/S cannot be calculated for Bonus Biogroup currently.

The Eulerpool Quality Score for Bonus Biogroup is 2/10.

The ISIN of Bonus Biogroup is IL0004850116. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Bonus Biogroup is A0Q9T6. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Bonus Biogroup is BONS.TA. The ticker symbol is used to trade Bonus Biogroup shares on the stock exchange.

Bonus Biogroup paid dividends every year for the past 0 years.

Bonus Biogroup is assigned to the 'Health' sector.

The dividends of Bonus Biogroup are distributed in ILS.

All fundamentals and in-depth analysis of Bonus Biogroup

Our stock analysis for Bonus Biogroup stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bonus Biogroup. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Bonus Biogroup Stock
Bonus Biogroup Revenue→
Bonus Biogroup Stock
Bonus Biogroup Net Income→
Bonus Biogroup Stock
Bonus Biogroup P/E→
Bonus Biogroup Stock
Bonus Biogroup P/S→
Bonus Biogroup Stock
Bonus Biogroup EBIT→
Bonus Biogroup Stock
Bonus Biogroup Dividend→
Bonus Biogroup Stock
Bonus Biogroup Directors Dealings→
Bonus Biogroup Stock
Bonus Biogroup Stocks→
Bonus Biogroup Stock
Bonus Biogroup Market capitalization→
Bonus Biogroup Stock
Bonus Biogroup Debt→
Bonus Biogroup Stock
Bonus Biogroup Liabilities→
Bonus Biogroup Stock
Bonus Biogroup Equity→
Bonus Biogroup Stock
Bonus Biogroup AAQS→
Bonus Biogroup Stock
Bonus Biogroup Employees→
Bonus Biogroup Stock
Bonus Biogroup ROE→
Bonus Biogroup Stock
Bonus Biogroup ROA→
Bonus Biogroup Stock
Bonus Biogroup ROCE→
Bonus Biogroup Stock
Bonus Biogroup News→
Bonus Biogroup Stock
Bonus Biogroup Analyst Price Targets→

Health Stocks

Borosil ScientificBonraybio CoBoryungBonesupport HoldingBoston ScientificBone BiologicsBotanix PharmaceuticalsBolt BiotherapeuticsBoule DiagnosticsBoji Medical Technology CoBoundless BioBoironAll Stocks A–Z →